Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta

被引：42

作者：

Wekre L.L. ^{[1
]}

Eriksen E.F. ^{[2
]}

Falch J.A. ^{[3
]}

机构：

[1] TRS National Resource Centre for Rare Disorders, Sunnaas Rehabilitation Hospital, University of Oslo

[2] Department of Endocrinology, Faculty of Medicine, University of Oslo, Oslo

[3] Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo

来源：

Archives of Osteoporosis | 2011年 / 6卷 / 1-2期

关键词：

Adult; Bone marker; Bone mineral density; Osteogenesis imperfecta; Osteoporosis;

D O I：

10.1007/s11657-011-0054-z

中图分类号：

学科分类号：

摘要：

Summary Still little is known about the manifestations of osteogenesis imperfecta (OI) in adults. We therefore initiated this study of bone mass, bone turnover and prevalence of fractures in a large cohort of adult patients. We found a surprising low prevalence (10%) of osteoporosis. These patients, however, expressed the most severe disease. Purpose To characterize bone mineral density, bone turnover, calcium metabolism and prevalence of fractures in a large cohort of adults with osteogenesis imperfecta. Methods One hundred fifty-four patients with adult OI participated and 90 (age range 25-83) provided dual X-ray absorptiometry (DXA) measurements. According to Sillence classification criteria, 68 persons were classified as OI type I, 9 as type III, 11 type IV and 2 were unclassified. Fracture numbers were based on self-reporting. Biochemical markers of bone turnover were measured and bone mineral density (BMD) of the spine, femoral neck and total body were determined by DXA. Results Only 10% of adults with OI exhibited osteoporotic T scores (T≤-2.5) but compared to patients with normal T scores this subgroup had a threefold higher fracture risk (22 vs. 69). s-PTH, s-Ca and 25[OH] vitamin D were all normal. Bone markers did not display major deviations from normal, but patients with OI type III displayed higher resorption marker levels than type I and IV. Multivariate regression analysis showed that only gender and total body BMD were significant determinants of fracture susceptibility, and the differences for total body BMC, BMD and Z scores were significant between the OI subtypes. Conclusions In adult OI, DXA measurements only identified few patients as osteoporotic. These patients, however, exhibited a much higher fracture propensity. Due to deformities, low body height and pre-existing fractures, DXA assessment is complicated in this disease, and further studies are needed to work out how to minimize the impact of these confounders. © International Osteoporosis Foundation and National Osteoporosis Foundation 2011.

引用

页码：31 / 38

页数：7

共 32 条

[1]

Rowe W.D., Shapiro R.Y., Osteogenesis imperfecta, Metabolic Bone Disease and Clinical Related Disorders, pp. 659-701, (1990)

[2]

Sillence D.O., Senn A., Danks D.M., Genetic heterogeneity in osteogenesis imperfecta, Journal of Medical Genetics, 16, 2, pp. 101-116, (1979)

[3]

Glorieux F.H., Rauch F., Plotkin H., Ward L., Travers R., Roughley P., Et al., Type Vosteogenesis imperfecta: A new form of brittle bone disease, J Bone Miner Res, 15, pp. 1650-1658, (2009)

[4]

Glorieux F.H., Ward L.M., Rauch F., Lalic L., Roughley P.J., Travers R., Osteogenesis imperfecta type VI: A form of brittle bone disease with a mineralization defect, Journal of Bone and Mineral Research, 17, 1, pp. 30-38, (2002)

[5]

Ward L.M., Rauch F., Travers R., Chabot G., Azouz E.M., Lalic L., Roughley P.J., Glorieux F.H., Osteogenesis imperfecta type VII: An autosomal recessive form of brittle bone disease, Bone, 31, 1, pp. 12-18, (2002)

[6]

Roughley P.J., Rauch F., Glorieux F.H., Hofstetter W., Alini M., Osteogenesis imperfecta - Clinical and molecular diversity, European Cells and Materials, 5, pp. 41-47, (2003)

[7]

Viguet-Carrin S., Garnero P., Demas P.D., The role of collagen in bone strength, Osteoporos Int, 17, pp. 319-36, (2006)

[8]

Paterson C.R., McAllion S., Stellman J.L., Osteogenesis imperfecta after the menopause, New England Journal of Medicine, 310, 26, pp. 1694-1696, (1984)

[9]

Primorac D., Rowe D.W., Mottes M., Barisic I., Anticevic D., Mirandola S., Gomez Lira M., Kalajzic I., Kusec V., Glorieux F.H., Osteogenesis imperfecta at the beginning of bone and joint decade, Croatian Medical Journal, 42, 4, pp. 393-415, (2001)

[10]

Adami S., Gatti D., Colapietro F., Fracassi E., Braga V., Rossini M., Tato L., Intravenous neridronate in adults with osteogenesis imperfecta, Journal of Bone and Mineral Research, 18, 1, pp. 126-130, (2003)

← 1 2 3 4 →